Dangerous Monopoly: KRG’s Cancer Drug Crisis Exposed

Ali Hama Salih exposes the KRG’s monopolistic cancer drug procurement practices, highlighting increased patient suffering and profiteering by Globin Pharma Company.

The Kurdistan Regional Government (KRG) is facing severe backlash following revelations by Ali Hama Salih about its monopolistic cancer drug procurement practices. According to Salih, the KRG is required to purchase all cancer medications exclusively from Globin Pharma Company, a move that has sparked outrage and concern among healthcare professionals and patients alike.

This monopoly impacts around 140 types of cancer drugs, leaving no room for competition or choice. “There is no company! 140 types of cancer drugs! So he buys it back! There will be no competition, prices, and estimates! What this company brought you have to buy from it! Expensive or not, good or not! There will be a big crisis!!!” Salih reported, emphasizing the dire consequences of this procurement strategy.

The situation creates a dangerous precedent where the sole supplier, Globin Pharma Company, can dictate prices and quality without accountability. This lack of competition inflates prices and compromises the availability of essential medications, placing an undue financial and emotional burden on cancer patients.

“This is a clear monopoly and business over cancer patients! Who must this company belong to! This is a huge monopoly!” Salih questioned, pointing to potential conflicts of interest and corruption within the procurement process. The lack of transparency raises suspicions that high-ranking officials may have vested interests in Globin Pharma, prioritizing profit over patient care.

In hospitals across the region, people are suffering desperately, seeking donations to afford their medications. Meanwhile, the Kurdish government claims that everything is under control, starkly contrasting with the reality on the ground.

This monopoly is not just a business issue but a grave ethical concern, affecting the lives of countless cancer patients in the Kurdistan Region. As cancer cases rise, the profits of those controlling the drug market increase, highlighting a disturbing prioritization of financial gain over patient well-being.

The current system leaves patients and healthcare providers with no choice but to accept whatever Globin Pharma supplies, regardless of cost or effectiveness. This situation calls for immediate action to break the monopoly, ensure fair competition, and prioritize the health and safety of cancer patients.

One thought on “Dangerous Monopoly: KRG’s Cancer Drug Crisis Exposed

Leave a Reply

Your email address will not be published. Required fields are marked *